Sunvozertinib: the next candidate of TKI for NSCLC

The therapeutic landscape for non-small-cell lung cancer (NSCLC) with exon-20 insertion mutations (exon20ins) of the epidermal growth factor receptor (EGFR) gene is complex. Patients and health-care providers have long sought hope in the form of effective treatments that offer respite from relentless disease progression. To date, the EGFR tyrosine kinase inhibitors (TKIs), including osimertinib, that have been approved worldwide for patients with NSCLC who have the more common (vs exon20ins) activating mutations of EGFR—ie, exon-19 deletions and the L858R point mutation in exon 21—have proven largely ineffective for patients with exon20ins mutations,1 highlighting the dire unmet need for new therapeutic approaches.